TABLE 1.
Baseline characteristics (N = 35)
| Characteristics | N (%)/Median [range] |
|---|---|
| Age, years | 70 [43–79] |
| >65 years | 23 (66) |
| Male | 21 (60) |
| Diagnosis | |
| MDS/MPNU/CMML/aCML | 14 (40)/17 (49)/4 (11) |
| MF DIPSS | |
| Int-1/Int-2/High | 7 (20)/18 (51)/10 (29) |
| MDS IPSS | |
| Low/Int-1/Int-2/High | 14 (40)/14 (40)/6 (17)/1 (3) |
| MDS R-IPSS | |
| Very Low/Low/Int/High/ | 8 (23)/12 (34)/10 |
| Very High | (28)/3 (9)/2 (6) |
| MDA Global score | |
| Low/Int-1/Int-2/High | 3 (9)/20 (57)/9 (25)/3 (9) |
| Splenomegaly | 12/32 (38%) |
| Peripheral blood blasts ≥1% | 24 (69) |
| WBC [×109/L] | 26.3 [3–123.2] |
| Platelets [×109/L] | 170 [53–1429] |
| Hemoglobin [g/dL] | 10.1 [6.4–14.4] |
| LDH | 860 [409–3230] |
| Cytogenetics | |
| Diploid/Abnormal | 25 (71)/10 (29) |
| EUMNET Fibrosis Grade | |
| MF-1/MF-2/MF-3 | 17/29 (59)/8/29 (28)/4/29 (14) |
| Patients with prior treatment | 12 (34) |
| JAK2 mutation | 10 (29) |
| JAK2 allele burden (%) | 42.2 [3–90] |
| CALR mutation | 0/8 |
| MPL mutation | 1/34 (3) |
| Molecular (28-gene profile, N = 34) a | |
| ASXL1 | 7(21) |
| TET2 | 6(18) |
| KRAS | 5(15) |
| NRAS | 4(12) |
| DNMT3A | 4 (12) |
| PTPN11 | 3(9) |
| IDH2 | 2 (6) |
| RUNX1 | 1 (3) |
| GATA2 | 1 (3) |
a
Frequently identified mutations.
Abbreviations; Int: Intermediate; MDA: MD Anderson; WBC: white blood cell count; LDH: Lactate dehydrogenase; EUMNET: European myelofibrosis network.